LFAMarketsIndonesia

Clinical Lateral Flow Assay Markets in Indonesia

$ 1,200.00

The success of home-based pregnancy tests in lateral flow format has been instrumental in the growth of lateral flow immunoassay (LFIA) as a platform accepted across widely different application segments. Ease of use combined with accuracy in the majority of situations is driving the clinical use of LFIA tests for the diagnosis of various infectious diseases, cancer, cardiac disease, and drug of abuse tests.

While developed markets such as North America and Europe have the highest market demand for these products, the Asia-Pacific region is the fastest growing market for these tests. Indonesia’s healthcare market is on the verge of rapid growth at this point, as the government is taking steps to improve access to quality healthcare for its population by implementing universal health coverage (UHC) for 100% of its population by 2019.

Product Description

  • The success of home-based pregnancy tests in lateral flow format has been instrumental in the growth of lateral flow immunoassay (LFIA) as a platform accepted across widely different application segments. Ease of use combined with accuracy in majority of situations is driving the clinical use of LFIA tests for the diagnosis of various infectious diseases, cancer, cardiac disease, and drug of abuse tests.

    While developed markets such as North America and Europe have the highest market demand for these products, the Asia-Pacific region is the fastest growing market for these tests. The manufacturers are responding to the growing market demand by developing tests for several tropical infectious diseases including malaria, dengue, and typhoid. Apart from large markets such as China and India, many small countries are also indicating strong demand for these products. For instance, several Southeast Asian countries can be categorized under emerging markets for these products. One such key market in the region is Indonesia, mainly due to its large population of over 200 million and high prevalence of several infectious diseases.

    Indonesia’s healthcare market is on the verge of rapid growth at this point, as the government is taking steps to improve access to quality healthcare for its population by implementing universal health coverage (UHC) for 100% of its population by 2019. In addition to this, regulations promoting e-commerce as a measure to tackle corruption practices in the public sector is also changing the face of the healthcare system in Indonesia.

    In this report, AcuBiz Consulting analyses Indonesian demand for clinical LFIA rapid tests and forecasts its growth. The market size by unit shipments for these products is expected to grow at a CAGR of 13% between 2016 and 2021. However, revenue growth is expected to grow at a lower rate, at around 10.2%. The increasing significance of community healthcare centers in Indonesia as primary healthcare providers is one of the major factors driving this growth. However, e-commerce regulations are expected to impact revenues and profit margins from these products.

    This report assesses the regulatory landscape of the healthcare sector with a particular focus on the criteria important for foreign companies interested in this market. It also assesses the prevalence of various diseases in each province of Indonesia, which is critical for companies to develop strategies based on the tests that will have the highest demand. Finally, the report analyses key brands available in Indonesia, its manufacturers, and distributors.

  • Executive Summary

    Introduction
    Study Goal and Outline
    Rational for this Study
    Targeted Audience
    Market Definition and Scope
    Information Sources
    Methodology
    Customization of the Study
    Disclaimer
    Background of the Study

    Chapter 1: Market Overview
    General Characteristics of the Indonesian Market
    Overview of Indonesia’s Healthcare Market
    Table 1: Key Market Trends and Drivers Influencing Indonesia’s Healthcare Sector
    Figure 1: Indonesia – Healthcare Delivery System
    Table 2: Number of Hospitals in Indonesia by Ownership, 2016
    Figure 2: Hospital Industry Landscape, 2017
    Upcoming Investments in Private Healthcare Segment in Indonesia
    Table 3: Distribution of Community Healthcare Centers (CHCs) in Indonesia
    Table 4: Distribution of Medical Device Distributors in Indonesia
    Indonesia’s Healthcare Sector: Market Challenges
    Table 5: Key Market Challenges of Indonesia’s Healthcare Sector

    Chapter 2: Regulatory Trends & Insights Relevant for IVD Sector
    Processes for Distribution License, Company & Product Registrations
    Table 6: Licenses Required for IVD Distribution
    Market Transition to E-Catalogue and Related Regulations
    Regulations for Foreign Direct Investments
    Table 7: Contact Details of BKPM Offices Worldwide for Investing in Indonesia
    The Impact of Negative List on FDI
    Setting up a Company in Indonesia: Tips for Foreign Investors
    Options for an IVD Company to Enter Indonesian Market
    Table 8: Options for a Foreign IVD Company to Enter Indonesian Market
    Business Strategies Adopted by MNCs: Case Studies
    Important factors to consider while choosing IVD Distributor in Indonesia

    Chapter 3: Industry Structure
    Indonesian Market Landscape for LFIA-Based Rapid Tests
    Why LFIA-Based Rapid Tests?
    Assessment of End-Users
    Demand Trends in Indonesian Red Cross Segment
    Demand Trends in Government sector
    Demand Trends in Private sector
    Figure 3: Market Segmentation by End-User Categories
    Supplier Trends: Leading Brands in Indonesia
    Table 9: Popular LFIA-based Rapid Test Brands and their Distributors in Indonesia
    Supplier Trends: Assessment of Rapid Test Distributors
    Common Infectious Diseases and Demand for Rapid Tests for Diagnosing them in Indonesia
    Market Size and Market Forecast (2016-2021)
    Figure 4: Market Forecast for Clinical LFIA-Based Rapid Tests, By Revenues
    (2016-2021)

    Chapter 4: Statistics of Highly Prevalent Infectious Diseases in Indonesia
    Table 10: Pulmonary Tuberculosis Cases by Province – 2013
    Table 11: HIV Cases BY Province, 2013
    Table 12: Malaria Cases and Prevalence in Indonesia by Province – 2014
    Table 13: Dengue Hemorrhagic Fever (DHF) Cases by Province – 2013
    Table 14: Filariasis Cases by Province – 2012-2014
    Table 15: Leptospirosis Cases by Province – 2013
    Table 16: Typhoid Prevalence in Indonesia

    Chapter 5: Company Profiles
    Profiles of Manufacturers of Top LFIA-Based Rapid Test Brands in Indonesia
    Alere Inc.
    CTK Biotech, Inc
    PT Fokus Diagnostic Indonesia
    PT Oncoprobe Utama
    Figure 4: Distribution Coverage of PT Oncoprobe Utama
    InTec Products Inc.
    Blue Cross Bio-Medical (Beijing) Co., Ltd.
    bioMerieux SA
    Table 17: bioMerieux Rapid Test Portfolio
    Nova Century Scientific, Inc
    Profiles of Rapid Test Distributors in Indonesia
    PT Anugrah Argon Medika (AAM)
    PT Enseval Putera Megatrading (EPM)
    PT Enseval Medika Prima (EMP)
    Figure 5: Enseval Group Structure
    Figure 6: Logistics Coverage of EPM
    PT Rajawali Nusindo
    Figure 7: Logistics Coverage of Rajawali Nusindo
    PT Primarindo Multi Alkestama
    Figure 8: Market Coverage of Primarindo
    PT Pacific Biotekindo Intralab
    PT Syifana Berkah Indonesia
    PT Sekarguna Medika

    Glossary

     

  • Alere Inc.
    CTK Biotech, Inc
    PT Fokus Diagnostic Indonesia
    PT Oncoprobe Utama
    InTec Products Inc.
    Blue Cross Bio-Medical (Beijing) Co., Ltd.
    bioMerieux SA
    Nova Century Scientific, Inc
    PT Anugrah Argon Medika (AAM)
    PT Enseval Putera Megatrading (EPM)
    PT Enseval Medika Prima (EMP)
    PT Rajawali Nusindo
    PT Primarindo Multi Alkestama
    PT Pacific Biotekindo Intralab
    PT Syifana Berkah Indonesia
    PT Sekarguna Medika